Castle Creek Biosciences, Inc.

Castle Creek Biosciences, Inc.

生物技术研究

Exton,Pennsylvania 2,966 位关注者

Dedicated to making life better for people living with genetic diseases

关于我们

Castle Creek Biosciences is a late-stage company developing re-dosable gene therapies. It is preparing to launch a pivotal clinical trial of its lead candidate, D-Fi, for patients with dystrophic epidermolysis bullosa (DEB).

网站
https://castlecreekbio.com
所属行业
生物技术研究
规模
11-50 人
总部
Exton,Pennsylvania
类型
私人持股
创立
2020
领域
Gene therapy、Rare disease、Clinical research、Drug development、Dermatology、Epidermolysis Bullosa、Life sciences、Personalized medicine、Biotechnology、Genetics、Orphan drug、Pediatric disease和Bioscience

地点

  • 主要

    405 Eagleview Blvd

    US,Pennsylvania,Exton,19341

    获取路线

Castle Creek Biosciences, Inc.员工

动态

相似主页

查看职位

融资